Star Scientific (CIGX) announced that it has completed a “Research and Royalty Agreement” with the Roskamp Institute’s affiliate, SRQ Bio, LLC, under which the Institute will conduct research on a compound developed by the company’s Rock Creek Pharmaceutical subsidiary that medical researchers at the Institute believe may have an application in the treatment of Alzheimer’s disease.
Preliminary testing of the compound has produced promising results when applied to cells, and the compound is being explored further for its application to treat a variety of neurological conditions, including Alzheimer’s. – PRN
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply